Changes in glomerular filtration rate after cardiac surgery with cardiopulmonary bypass in patients with mild preoperative renal dysfunction
Cardiac surgery with cardiopulmonary bypass (CPB) is commonly perceived as a risk factor for decline in renal function, especially in patients with preoperative renal dysfunction. There are few data on the effects of CPB on renal function in patients with mild preoperative renal dysfunction. The pur...
Saved in:
Published in | British journal of anaesthesia : BJA Vol. 100; no. 6; pp. 759 - 764 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ltd
01.06.2008
Oxford University Press Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Cardiac surgery with cardiopulmonary bypass (CPB) is commonly perceived as a risk factor for decline in renal function, especially in patients with preoperative renal dysfunction. There are few data on the effects of CPB on renal function in patients with mild preoperative renal dysfunction. The purpose of this study was to evaluate renal function in patients with pre-existing mild renal dysfunction undergoing cardiac surgery with CPB.
In a multicentre study cohort we measured prospectively the glomerular filtration rate (GFR) by radioactive markers both before operation and on the 7th postoperative day in cardiac surgical patients with preoperative serum creatinine >120 μmol l−1 (n=56). In a subgroup of patients (n=14) in addition to the GFR, the effective renal plasma flow (ERPF) and the filtration fraction (FF) were measured.
While preoperative GFR [77.9 (25.5) ml min−1] increased to 84.4 (23.7) ml min−1 (P=0.005) 1 week after surgery, ERPF did not change [295.8 (75.2) ml min−1 and 295.9 (75.9) ml min−1, respectively; P=0.8]. In accordance, the FF increased from 0.27 (0.05) (before operation) to 0.30 (0.04) (Day 7, P=0.01).
Our results oppose the view that cardiac surgery with CPB adversely affects renal function in patients with preoperative mild renal dysfunction and an uncomplicated clinical course. |
---|---|
Bibliography: | ArticleID:aen081 istex:D675F2AD21A4F7A1CC042B3CF700800E06FE291A ark:/67375/HXZ-D5SKH0B1-W Declaration of interest. A. J. Rankin is a research employee of Pfizer Global Research and Development, Kent, UK. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0007-0912 1471-6771 |
DOI: | 10.1093/bja/aen081 |